// App-Quantinova.ai

: The Anti‐factor XIa Antibody BAY 1213790 Shows Dose‐dependent Antithrombotic Efficacy without an Increased Risk of Bleeding on Top of Antiplatelet Treatment in Rabbits

Researchers

Presenter

  • A. Buchmueller

Principal Investigators

  • C. Gerdes

  • A. Wilmen

  • S. Heitmeier

  • V. Laux

Medical Centers

  • Bayer Pharma AG, Berlin, Germany

  • Bayer AG, Köln, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

Disease

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • BAY-1213790

  • Ticagrelor

  • Aspirin

  • Albyl-E

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved